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Introduction
Myelodysplastic syndromes (MDS) are clonal disorders of bone marrow stem cells characterized by ineffective hemopoiesis, leading to blood cytopenias and by a high incidence of progression to acute myeloid leukemia. [1] [2] [3] Prognosis of MDS with excess of marrow blasts remains poor. Allogeneic stem cell transplantation and, in selected cases, anthracycline/cytarabine based chemotherapy are the only curative approaches, but they can only be applied to a minority of cases. [4] [5] [6] [7] Less intensive therapy with low-dose cytarabine, decitabine, HMBA, low-dose melphalan, give 20% to 30% responses, generally transient, without any clear survival benefit demonstrated when compared to supportive care alone. [8] [9] [10] [11] [12] Topotecan, a DNA topoisomerase-I inhibitor has recently shown activity in high-risk MDS, alone or in combination with cytarabine. 13, 14 In the present study, we used CPT-11, another DNA topoisomerase-I inhibitor with a different spectrum of activity and toxicity, in 26 patients with MDS with an excess of marrow blasts who could not receive anthracycline/cytarabine intensive chemotherapy.
Patients and methods

Patients
Between July 1999 and November 2000, 26 patients with MDS and an excess of marrow blasts (у5%) were enrolled in the study. Eligibility criteria were: (1) Age greater than 65 years (or less than 65 in case of contraindication to intensive therapy); (2) One of the following types of MDS: refractory anemia with excess of blasts (RAEB), RAEB in transformation (RAEB-T); chronic myelomonocytic leukemia with poor prognosis characteristics (visceral involvement, marrow blasts у10% or two of the following criteria: white blood cells Ͼ12 × 10 9 /l, platelet count Ͻ100 × 10 9 /l, Hb Ͻ10 g/dl. Splenomegaly Ͼ5 cm below the margin costal) and MDS having progressed to acute myelogenous leukemia (MDS-AML); (3) PS Ͻ2 (WHO criteria) and life expectancy Ͼ12 weeks; (4) Adequate liver (bilirubin Ͻ1.25 × normal value and transaminase Ͻ3 × normal value) and renal function; (5) Informed consent given.
Treatment schedule, response and toxicity criteria
CPT-11 was administered intravenously over 90 min at 200 mg/m 2 every 2 weeks for a total of four courses (induction therapy). Response was assessed 2 weeks after the theorical date of the last induction course (day 60 of induction) according to IWG guidelines. 15 Toxicity was graded according to World Health Organization (WHO) grading system except for diarrhea which can be a major side-effect of CPT-11, 16 and was graded as: grade 1, diarrhea not requiring treatment; grade 2, diarrhea requiring treatment; grade 3, diarrhea requiring hospitalization and/or intravenous fluids; grade 4, diarrhea with blood or mucus).
At the first diarrhea episode, 2 mg of loperamide (imodium; Janssen Laboratories, Boulogne-Billancourt, France) were taken orally every 2 h during the day and if possible during the night until a12-h diarrhea-free interval. If, at the end of 3 consecutive days of continuous loperamide intake, diarrhea was not controlled and/or the patient was dehydrated, loperamide was stopped and the patient hospitalized and intravenous fluids administered. If blood or mucus was found in the stools at any time, loperamide was stopped and the patient was hospitalized.
Duration of neutropenia was calculated from the day granulocyte count became lower than the patient's baseline value (or less than 500/mm 3 ) to the day granulocyte count reached the same or a higher count than at baseline.
Trial design
Based on activity of other anticancer agents in patients with high-risk MDS unable to receive anthracyclin-based chemotherapy, a response rate of 40% was considered encouraging. The first step was to include 12 patients. If less than three of 12 achieved a response, the trial was stopped. If more than three of 12 responded, 15 additional patients were to be enrolled.
Results
Study group
Twenty-six patients were treated including: 11 RAEB (subclassified according to WHO classification in four AREB-1 and seven RAEB-2); five CMML and 10 MDS-AML. Patient characteristics are shown in Table 1 . Twenty-one males and five females were included with a median age of 71 years (range 51-77, 85% patients aged greater than 65 years). The four patients aged less than 65 years had not been treated with intensive chemotherapy due to active infectious disease (two patients) or severe cardiovascular disease (two patients).
Neutropenia less than 500/mm 3 and thrombocytopenia less than 50 000 were found in 14 (54%) and 17 (65%) patients, respectively. The median percentage of marrow blast cells was 13.5 % (range 7-52%). Cytogenetic classification according to International Prognosis Scoring System (IPSS) was lowrisk in 13 cases, intermediate-risk in six cases and high-risk in three cases. 17 Cytogenetic analysis failed in four cases.
Response to therapy and outcome
Six patients received only one or two courses of CPT-11 due to development of invasive fungal infectious disease in two cases (lung aspergillosis and candidemia, respectively), disease progression to overt acute myelogenous leukemia in three cases and tumor lysis syndrome with acute renal failure after the second course of CPT-11 in one CMML case. Twenty of the 26 patients received at least three courses of CPT-11 and were evaluated for response on day 60 of therapy. One of them (MDS-AML with trisomy 8) achieved complete hematological and cytogenetic remission, four achieved partial remission (one patient with RAEB-2 and three with MDS-AML) and three achieved hematological improvement: Two of the three patients with hematological improvement reached less than 5% bone marrow cells, but with persistent pancytopenia (one major erythroid response and one major platelet response) and the third patient, with CMML, showed disappearence of pleural effusion, splenomegaly and blood monocytosis, but bone marrow blasts remained higher than 5%. Duration of complete remission was 5 months, of partial remissions 2, 3, 6 and 6 months, respectively, and hematological improvements were 6, 8 and 8 months, respectively. Therefore, the response rate was 8/26 (33%) and 8/23 (35%) if the three patients who had early discontinuation of treatment due to tumor lysis syndrome or early invasive fungal infection were excluded. Median duration of response was short (4 months, range 1-6 months) and median survival was 8 months (range 1-23 months) for the whole group and 12 months (range 6 to 18 months) in patients who responded to CPT-11 ( Figure 1 ).
Toxicity
Toxicity was assessed in 89 courses. Two invasive fungal infections were observed during the first weeks of therapy (grade 4 infections). One case of acute renal failure related to tumor lysis syndrome was observed (grade 3 renal toxicity). Digestive toxicity (diarrhea) occurred in 26 (29%) courses, but was mild (grade 1: 20% courses, grade 2: 6% of courses and grade 3: 3% of courses). Three patients needed hospitalization for diarrhea. Hematological toxicity was difficult to assess in non-responders because of initial pancytopenia, but all patients who responded had grade 3/4 hematological toxicity with a median duration of 7 days (range 0-30). Grade у2 infection requiring hospitalization was observed in 18% courses. No other major toxicity was observed. Overall, 25% of CPT-11 courses required hospitalization for supportive care.
Discussion
Irinotecan hydrochloride (CPT-11), a unique DNA topoisomerase-I inhibitor, is widely used in the treatment of colorec-
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tal, breast, lung, ovarian and skin cancer. 18 CPT-11 activity is not modified by P-glycoprotein and has minimal cross-resistance with doxorubicin. 19 The mechanism of action of this new class of anticancer drugs is different from that of cytarabine and DNA topoisomerase-II inhibitors (anthracyclines, epipodophylotoxins), widely used in AML and high-risk MDS.
Only few studies have been performed with CPT-11 in hematological malignancies, [20] [21] [22] [23] most of them in lymphomas. [20] [21] [22] [23] Only one early phase II study that included leukemia patients was published to our knowledge. 20 In this study four different CPT-11 schedules were tested: 200 mg/m 2 /day every 3-4 weeks, 40 mg/m 2 /day for 5 days every 3-4 weeks, 40 mg/m 2 /day for 3 days every week and 20 mg/m 2 /day twice a day every 3-4 weeks. When the four schedules were analyzed together, CPT-11 activity was observed in 25% of relapsed or refractory acute leukemias. 20 To our knowledge, no previous study has been reported with CPT-11 in MDS.
In the present study, significant activity of CPT-11in MDS with excess of marrow blasts was observed. Seven of the eight responders had disappearance of their excess of blasts in the bone marrow with one complete remission and four partial remission. All patients with RAEB or RAEB-T who responded had a decrease of marrow blasts to less than 5% in their bone marrow. We considered that the patient with CMML had a clinical improvement since symptomatic pleural effusion needing successive evacuations, peripheral monocytosis and splenomegaly resolved for 5 months despite persistent excess of marrow blasts.
The most common CPT-11 associated toxicity is digestive. 24, 25 Delayed-onset diarrhea was observed in less then 1/3 of cases and was improved by the administration of oral loperamide as previously recommended. 16, 25 Cholinergic syndrome was not observed in our patients, and this complication has been mainly observed with CPT-11 doses greater than 240 mg/m 2 every 3 weeks. 16, 25 Most of the patients could be treated in the out-clinic setting with grade у2 infection requiring hospitalization in less than 25% of cycles.
Topotecan, another DNA topoisomerase-I inhibitor, has shown activity in high-risk myelodysplastic syndromes with CR in up to 32% of patients. 13, 14 These results, observed in CMML, RAEB and RAEB-T seem to be better than those we observed with CPT-11, but with greater hematological toxicity. Indeed, when topotecan was given alone, median time to recovery of granulocytes and platelets was 26 and 30 days, respectively, whereas with CPT-11, at the dose we tested (median duration of neutropenia was 7 days and only 25% of courses required patient hospitalization. 13 These results show that CPT-11 has some activity in MDS with excess of blasts and easily manageable toxicity, most patients being treated in the out-clinic setting. Further evaluation of CPT-11 in MDS is warranted, especially in combination with other drugs.
